FDA recall D-0767-2026

Regeneron Pharmaceuticals Inc · Class II · drug

Product

Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01

Reason for recall

Lack of Assurance of Sterility

Distribution

USA Nationwide

Key facts

Status
Ongoing
Initiation date
2026-07-28
Report date
2026-08-26
Voluntary/Mandated
Voluntary: Firm initiated
Location
Tarrytown, NY, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0767-2026